Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population
The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.
Evaluating Proactive Outreach for Prior Authorization Recertifications in Medicaid Patients
Implementing a proactive provider outreach program resulted in significantly more prior authorization recertifications and a reduction in time to submission.
